Drugs involved in drug-facilitated crimes: Part I: Alcohol, sedative-hypnotic drugs, gamma-hydroxybutyrate and ketamine. A review;Les substances de la soumission chimique: Partie I: Alcool, substances sédatives et hypnotiques, acide gamma hydroxybutyrique et kétamine. Revue

Annales Pharmaceutiques Francaises

Volumn 68, Issue 5, 2010, Pages 275-285

  Shbair, M K S ^a,b   Eljabour, S ^b   Lhermitte, M ^a,c  

^a UNIV LILLE   (France)

^b AL AZHAR UNIVERSITY   (Palestine)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Drug facilitated crimes; Ethanol; Gamma hydroxybutyrate; Ketamine; Sedative hypnotic drugs

Indexed keywords

3 HYDROXYBENZODIAZEPINE DERIVATIVE; 4 HYDROXYBUTYRIC ACID; 7 NITROBENZODIAZEPINE; ALCOHOL; ALPRAZOLAM; AMOBARBITAL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CENTRAL DEPRESSANT AGENT; CHLORAL HYDRATE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; FLUNITRAZEPAM; HYPNOTIC AGENT; KETAMINE; LORAZEPAM; MIDAZOLAM; PENTOBARBITAL; SECOBARBITAL; SEDATIVE AGENT; THIAMYLAL; THIOPENTAL; TRIAZOLAM; TRIAZOLOBENZODIAZEPINE DERIVATIVE; TUINAL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AMNESIA; ANXIETY DISORDER; APNEA; ASSAULT; BRADYCARDIA; COGNITIVE DEFECT; COMA; CONFUSION; CRIME; DELUSION; DEPERSONALIZATION; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG ELIMINATION; DRUG FACILITATED CRIME; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MISUSE; DRUG OVERDOSE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPOTENSION; HYPOTHERMIA; INSOMNIA; LOW DRUG DOSE; MEMORY DISORDER; MOTOR DYSFUNCTION; NAUSEA; NYSTAGMUS; PANIC; PERCEPTION DISORDER; RESPIRATION DEPRESSION; REVIEW; SCHIZOPHRENIA; SEIZURE; SKIN MANIFESTATION; SOMNOLENCE; THEFT; UNCONSCIOUSNESS; VISUAL DISORDER; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; VOMITING;

EID: 77956708957     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2010.05.002     Document Type: Review

References (101)

1. Hurley M., Parker H., Wells D. The epidemiology of drug facilitated sexual assault. J Clin Forensic Med 2006, 13:181-185.
2. Hindmarch I., Elsohly M., Gambles J., Salamone S. Forensic urinalysis of drug use in cases of alleged sexual assault. J Clin Forensic Med 2001, 8:197-205.
3. Wells D. Drug administration and sexual assault: sex in a glass. Sci Just 2001, 41:197-199.
4. LeBeau M. Toxicological investigations of drug-facilitated sexual assaults. Forensic Sci Commun 1999, 1:12.
5. Society of Forensic Toxicologists (SOFT) drug-facilitated sexual Assault Committee. Recommended maximum detection limits for common DFSA drugs and metabolites in urine samples. Available from: URL: [accessed 2009 Dec 25]. http://www.softtox.org/docs/SOFT%2520DFSA%2520list.pdf.
6. Société française de toxicologie analytique (SFTA). Consensus SFTA 2003. Soumission chimique: prise en charge toxicologique. Available from: URL: [accessed 2009 Dec 25]. http://www.smlc.asso.fr/smlc/dmla/toxicologie/pdf/consensus_SFTA.pdf.
7. LeBeau M.A. Guidance for improved detection of drugs used to facilitate crimes. Ther Drug Monit 2008, 30:229-233.
8. LeBeau M.A., Mozayani A. Drug-facilitated sexual assault. A Forensic Handbook 2001, Academic Press, London.
9. Schwartz R.H., Milteer R., LeBeau M.A. Drug facilitated sexual assault (date rape). South Med J 2000, 93:558-561.
10. Dorandeu A.H., Pagès C.A., Sordino M.C., Pépin G., Baccino E., Kintz P. A case in south-eastern France: a review of drug facilitated sexual assault in European and English-speaking countries. J Clin Forensic Med 2006, 13:253-261.
11. Pépin G., Deveaux M., Chèze M., Hoizey G. La soumission chimique. Expérience du laboratoire Toxlab après 900 réquisitions judiciaires. Experts 2009, 87:20-26.
12. Bismuth C., Dally S., Borron S.W. Chemical submission: GHB, benzodiazepines, and other knock out drops. J Toxicol Clin Toxicol 1997, 35:595-598.
13. Papadodima S.A., Athanaselis S.A., Spiliopoulou C. Toxicological investigation of drug-facilitated sexual assaults. Int J Clin Pract 2007, 61:259-264.
14. Hall J.A., Moore C.B. Drug-facilitated sexual assault. A review. J Forensic Leg Med 2008, 15:291-297.
15. Young A.M., Morales M., McCabe S.E., Boyd C.J., Darcy H. Drinking like a guy: frequent binge drinking among undergraduate women. Subs Use Misuse 2005, 40:241-267.
16. Anderson DS. 2008 College alcohol survey Results. George Mason University. Available at: URL: [accessed 2009 Oct 12]. http://www.caph.gmu.edu./research/htm.
17. Health promotion agency and Irish temperance League. Drinking behaviour among young people in Northern Ireland. Available from: URL: [accessed 2009 Oct 18]. http://www.healthpromotionagency.org.uk/Resources/alcohol/pdfs/temperanc ereport.pdf.
18. Hope J. Drug rape myth exposed as study reveals binge drinking is to blame. Daily Mail 2007. Available at: URL: [accessed 2009 Oct 12]. http://www.dailymail.co.uk/news/article-436529.
19. Goist K.C., Sutcker P.B. Acute alcohol intoxication and body composition in women and men. Pharmacol Biochem Behav 1985, 22:811-814.
20. Jones A.W., Kugelberg F.C., Holmen A., Ahlner J. Occurrence of ethanol and other drugs in blood and urine specimens from female victims of alleged sexual assault. Forensic Sci Int 2008, 181:40-46.
21. Scott-Hamm M., Burton F.C. Study of blood and urine alcohol concentrations in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 2006, 13:107-111.
22. Paul R., Kingston R., Tsanaclis L., Berry A., Guwy A. Do drug users use less alcohol than non-drug users? A comparison of ethyl glucuronide concentrations in hair between the two groups in medicolegal cases. Forensic Sci Int 2008, 176:82-86.
23. Foti R.S., Fisher M.B. Assessment of UDP-glucuronosyltransferase catalyzed formation of ethyl glucoronide in human liver microsomes and recombinant UGTs. Forensic Sci Int 2005, 153:109-116.
24. Wurst F.M., Dresen S., Allen J.P., Weisbec K.G., Graf M., Weinmann W. Ethyl sulphate: a direct ethanol metabolite reflecting recent alcohol consumption. Addiction 2006, 101:204-211.
25. A receptors to increase tonic inhibition. Alcohol 2007, 41:211-221.
26. Weight F.F., Aguayo L.G., White G., Lovinger D.M., Peoples R.W. GABA-and glutamate-gated ion channels as molecular sites of alcohol and anaesthetic action. Adv Biochem Psychopharmacol 1992, 47:335-347.
27. Scott-Ham M., Burton F. Toxicological findings in cases of alleged-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 2005, 12:175-186.
28. Anderson R.A., Ariffin M.M., Cormack P.A., Miller E.I. Comparison of molecularly imprinted solid-phase extraction (MISPE) with classical solid-phase extraction (SPE) for the detection of benzodiazepines in post-mortem hair samples. Forensic Sci Int 2008, 174:40-46.
29. Greenblatt D.J., Shader R.I., Divoll M., Harmatz J.S. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmac 1981, 1:11S-16S.
30. Goullé J.P., Anger J.P. Drug-facilitated robbery or sexual assault. Problems associated with amnesia. Ther Drug Monit 2004, 26:206-210.
31. Terzano M.G., Rossi M., Palomba V., Smerieri A., Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003, 26:261-282.
32. Stark M.M., Wells D. Drug-mediated sexual assault. J Clin Forensic Med 1999, 6:53-55.
33. Barbee J.G. Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. J Clin Psychiatry 1993, 54:86-101.
34. Thompson T. Rape Drug used to rob thousands. The Observer 2004.
35. Boussairi A., Dupeyron J.P., Hernandez B., Delaitre D., Beugnet L., Espinoza P., et al. Urine benzodiazepines screening of involuntary drugged and robbed or raped patients. Clin Toxicol 1996, 34:721-724.
36. Calhoun S.R., Wesson D.R., Galloway G.P., Smith D.E. Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and South Texas. J Psychoactive Drugs 1996, 28:183-189.
37. Agence française de sécurité sanitaire des produits de santé (Afssaps). Résultats Enquête nationale sur la soumission chimique 2007. Afssaps website (23/02/2009). Available from: URL: [accessed 2010 May 10]. http://www.afssaps.fr/var/afssaps_site/storage/original/application/9e5a 4955f3462697342a561b06fb8292.pdf.
38. Agence française de sécurité sanitaire des produits de santé (Afssaps). Résultats Enquête nationale sur la soumission chimique 2008. Afssaps website (26/03/2010) Available from: URL: [accessed 2010 May 10]. http://www.afssaps.fr/var/afssaps_site/storage/original/application/87d9 b3283e474c3552cbe87ff02d9437.pdf.
39. Negrusz A., Gaensslen R.E. Analytical development in toxicological investigation of drug-facilitated sexual assault. Anal Bioanal Chem 2003, 376:1192-1197.
40. Boxenbaum H.G., Posmanter H.N., Macasieb T., Geitner K.A., Weinfeld R.E., Moor J.D., et al. Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1978, 6:283-293.
41. Schwartz R.H., Weaver A.B. Rohypnol, the date rape drug. Clin Pediatr 1998, 37:321-322.
42. Amir L., Waisman Y. Medical and toxicological aspects of drug-facilitated sexual assault. Israeli J Emerg Med 2006, 6:62-66.
43. Waltzman M.L. Flunitrazepam: a review of " roofies" Pediatr Emerg Care 1999, 15:59-60.
44. Gahlinger P.M., Club Drugs: M.D.M.A. Gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. Am Fam Physician 2004, 69:2619-2626.
45. Rohypnol. Office of National Drug Control Policy. Drug Policy Information Clearinghouse. Fact Sheet. 2002. pp. 1-4.
46. Negrusz A, Juhascik M, Gaensslen RE. Estimate of the incidence of drug-facilitated sexual assault in the US. Final report, 2005.
47. Djezzar S., Questel F., Burin E., Dally S. Chemical submission: results of " 4-year French inquiry" Int J Legal Med 2009, 123:213-219.
48. Chèze M., Deveaux M., Lenoan A., Pépin G. Clonazepam, bromazepam and zolpidem in hair victims of drug facilitated crimes: quantitative analysis by LC-MS/MS and correlation with self-report. Ann Toxicol Anal 2005, 17:269-273.
49. Elian A.A. Elisa detection of clonazepam and 7-aminoclonazepam in whole blood and urine. Forensic Sci Int 2003, 134:54-56.
50. Nergusz A., Bowen A.M., Moore C.M., Dowd S.M., Strong M.J., Janicak P.G. Elimination of 7-aminoclonazepam in urine after a single dose of clonazepam. Anal Bioanal Chem 2003, 376:1198-1204.
51. Baselt R.C. Disposition of toxic drugs and chemicals in Man 2004, Biomedical Publications, Foster city, California, USA, p. 235. Six ed.
52. Parfitt K. Martindale, the complete drug reference. Pharmaceutical Press; 1999. p. 343.
53. ®: victim and/or consumer?. Ann Toxicol Anal 2009, 21:155-158.
54. Chèze M., Villain M., Pépin G. Determination of bromazepam, clonazepam and metabolites after a single intake in urine and hair by LC-MS/MS. Application to forensic cases of drug-facilitated crimes. Forensic Sci Int 2004, 145:123-130.
55. Baselt R.C. Disposition of toxic drugs and chemicals in Man 2004, Biomedical Publications, Foster city, California, USA, p. 116. Six ed.
56. Kintz P., Villain M., Cirimile V., Pépin G., Ludes B. Windows of detection of lorazepam in urine, oral fluid and hair, with a special focus on drug-facilitated crimes. Forensic Sci Int 2004, 145:131-135.
57. Kyriakopoulos A.A., Greenblatt D.J., Shader R.I. Clinical pharmacokinetics of lorazepam: a review. J Clin Psychiatry 1987, 39:16-23.
58. Elliott H.W. Metabolism of lorazepam. Br J Anaesth 1976, 48:1017-1023.
59. Greenblatt D.J. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981, 2:89-105.
60. Preston G.C., Broks P., Taurb M., Ward C., Poppleton P., Stahl S.M. Effects of lorazepam on memory, attention and sedation in man. Psychopharmacol 1988, 95:208-215.
61. Blin O., Simon N., Jouve E., Habib M., Gayraud D., Durand A., et al. Pharmacokinetic and pharmacodynamic analysis of sedative and amnesic effects of lorazepam in healthy volunteers. Clin Neuropharmacol 2001, 24:71-81.
62. Blin O., Jacquet A., Callamand S., Jouve E., Habib M., Gayraud D., et al. Pharmacokinetic-pharmacodynamic analysis of amnesic effects of lorazepam in healthy volunteers. Br J Clin Pharmacol 1999, 48:510-512.
63. Bratzke H., Klug E. Drug-induced unconsciousness with subsequent criminal acts. Arch Kriminol 1988, 181:33-40.
64. Verster J.C., Volkerts E.R. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev 2004, 10:45-76.
65. Kelly T.H., Foltin R.W., Serpick E., Fischman M.W. Behavioral effects of alprazolam in humans. Behav Pharmacol 1997, 8:47-57.
66. Kankaria A., Lewis J.H., Ginsberg G., Gallagher J., Al-kawas F.H., Nguyen C.C. Flumazenil reversal of psychomotor impairment due to midazolam or diazepam for conscious sedation for upper endoscopy. Gastrointest Endosc 1996, 44:416-421.
67. Karahalil B., Yaĝar S., Bahadir G., Durak P., Şardaş S. Diazepam and propofol used as anesthetics during open-heart surgery do not cause chromosomal aberrations in peripheral blood lymphocytes. Mut Res 2005, 581:181-186.
68. Kant G.J., Wylie R.M., Vasilakis A.A., Ghosh S. Effects of triazolam and diazepam on learning and memory as assessed using water maze. Pharmacol Biochem Behav 1996, 53:317-322.
69. Bixler E.O., Kales A., Manfredi R.L., Vgontzas A.N., Tyson K.L., Kales J.D. Next-day memory impairment with triazolam use. Lancet 1991, 337:827-831.
70. Kintz P., Villain M., Ludes B. Testing for zolpidem in oral fluid by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2004, 811:59-63.
71. Logan B.K., Couper F.J. Zolpidem and driving impairment. J Forensic Sci 2001, 46:105-110.
72. Drover D., Lemmens H., Naidu S., Cevallos W., Darwish M., Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000, 22:1443-1461.
73. Villain M., Chèze M., Tracqui A., Ludes B., Kintz P. Testing for zopiclone in hair application to drug-facilitated crimes. Forensic Sci Int 2004, 145:117-121.
74. Hajak G., Muller W.E., Wittchen Hu, Pittrow D., Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003, 98:1371-1378.
75. Coupey S.M. Barbiturates. Pediatr Rev 1997, 18:260-264.
76. Barbiturates, toxicity. Available from: URL: [accessed 2009 Aug 20]. http://www.emedicine.medspace.com/article/813155-overview.
77. Gauillard J., Cheref S., Vancherontrydtrom M.N., Martin J.C. Chloral hydrate: a hypnotic best forgetton? Encephale 2002, 28:200-204.
78. Agence française de sécurité sanitaire des produits de santé (Afssaps). Afssaps website (07/09/2001). Conditions d'utilisation de l'hydrate de chloral. Available from: URL: [accessed 2010 May 10]. http://www.afssaps.fr//Infos-de-securite/lettres-au-profesionnels-de-san te/Conditions-d-utilisation-d-1-hydrate-de-chloral/(language)/fr-FR.
79. A drugs. J Clin Sleep Med 2006, 2:S19-S26.
80. Karila L., Novarian J., Megarbane B., Cottencin O., Dally S., Lowenstein W., et al. Acide gamma-hydroxy-butyrique (GHB): plus qu'un agent de soumission chimique, une véritable source d'addiction. Press Med 2009, 38:1526-1538.
81. Li J., Stokes S.A., Woeckneer A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations foe management. Ann Emerg Med 1998, 31:729-736.
82. Cohrs F.P., Porter W.H. Gamma-hydroxybutyrate intoxication and overdose. Ann Emerg Med 1999, 33:475-476.
83. Palatini P., Tedeschi L., Frison G., Padrini R., Zordan R., Orlando R., et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in health volunteers. Eur J Clin Phar 1993, 45:353-356.
84. Gahlinger P.M. Club Drugs: MDMA, Gamma-hydroxybutyrate (GHB). Rohypnol, and Ketamine. Am Fam Physcian 2004, 69:2619-2626.
85. Gamma Hydroxybutyrate (GHB). Office of National Drug Control Policy (ONDCP). Drug Policy Information Clearinghouse. Fact Sheet 2002, p. 1-4.
86. Couper F.J., Marinetti L.J. γ-hydroxybutyrate (GHB) - Effects on human performance and behavior. Forensic Sci Rev 2002, 14:101-121.
87. Chin M.Y., Kreutzer R.A., Dyer J.E. Acute poisoning from gamma-hydroxybutyrate in California. Western J Med 1992, 156:380-384.
88. Bosman I.J., Lusthof K.J. Forensic cases involving the use of GHB in the Netherlands. Forensic Sci Int 2003, 133:17-21.
89. Lora-Tamayo C., Tena T., Rodriguez A., Sancho J.R., Molina E. Intoxication due to 1,4-butanediol. Forensic Sci Int 2003, 133:256-259.
90. Pharmacon chemicals resource page. Order top quality Na-GHB powder online. Available from: [accessed 2009 Oct 12]. http://www.ghb-sales.com/.
91. University of Texas-Pelchat Laboratory. GHB synthesis from pelchat labs. Available from: [accessed 2009 Oct 12]. http://www.uts.cc.utexas.edu/~laborit/reactpel.html.
92. Kintz P., Villain M., Cirimele V., Ludes B. GHB in post-mortem toxicology. Discrimination between endogenous production from exposure using multiple specimens. Forensic Sci Int 2004, 143:177-181.
93. Elliott S., Burgess V. The presence of gamma-hydroxybutyric acid (GHB) and gamma-butyrolactone (GBL) in alcoholic and non alcoholic beverages. Forensic Sci Int 2005, 151:289-292.
94. Kohrs R., Durieux M.E. Ketamine: teaching an old drug new tricks. Anesth Analog 1998, 87:1186-1193.
95. Rommanelii F., Smith K.M. X Liquid E, and Special K - the abuse of drugs at clubs and raves. Am J Pharm Educ 2002, 66:195-199.
96. Freese T.E., Miotto K., Reback C.J. The effects and consequences of selected club drugs. J Subs Abuse Treat 2002, 23:151-156.
97. Jansen K.L. Non-medical uses of ketamine. Br Med J 1997, 19:53-63.
98. Wolff K., Winstock A.R. Ketamine: from medicine to misuse. CNS Drugs 2006, 20:199-218.
99. Zancy J.P., Galinkin J.L. Psychotropic drugs used in anesthesia. Practice, abuse, liability and epidemiology of abuse. Anesthesiology 1999, 90:269-288.
100. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Capiello A., et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch General Psych 2000, 57:270-276.
101. Parkin M.C., Turfus S.C., Smith N.W., Halket J.M., Braithwaite R.A., Elliot S.P., et al. Detection of ketamine and its metabolites in urine by ultra high-pressure liquid chromatography-tandem mass spectrometry. J Chromatogr B 2008, 876:137-142.